Expert Interview
A Third View: Delving into the phase 1/2 clinical trial data regarding Kyverna Therapeutics’ CAR-T therapeutic for autoimmune disease, KYV-101.
Ticker(s): KYTXInstitution: Cleveland Clinic
- Rheumatologist with a special interest in epidemiology of rheumatic diseases.
- Currently manages 300 patients with RA and 100 with SLE
- Research Focus: epidemiology of sarcoidosis and has published over 30 original articles describing this under-studied disease.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
